Analyst Reports
Trinity Life Sciences is a Leader in Everest Group’s 2025 Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment—with its distinction rooted in exceptional, tangible outcomes delivered for clients across the life sciences sector.
More about the report
Everest Group’s PEAK Matrix® is a framework to assess the overall vision, capability and market impact of platform providers.
The assessment is based on Everest Group’s PEAK Matrix® Request For Information process for the calendar year 2024, interactions with leading life sciences…
Read Now
Briefs
Through the 2020s, life sciences leaders have dealt with one challenge after another. The shock of the COVID-19 pandemic. Sticky inflation. Return-to-office mandates. The intense pressure to perform in the face of disruptive challenges has proven constant.
For commercial learning and development, also known as commercial L&D, this has presented new roadblocks and innovations alike, making data more important than ever to navigate a rapidly changing industry. That’s why TGaS Advisors, a Division of Trinity Life Sciences, in partnership with…
Read Now
Briefs
How are Commercial, Medical and Market Access organizations evolving to develop capabilities and accelerate innovation in 2025 and beyond?
Executive leaders are focused on making informed organizational decisions to propel the evolution of capabilities in this rapidly changing global economy. As you strategize to optimize structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ 2025 Spring Summit.
Complete the form below to access the advisory brief.
By submitting this form,…
Read Now
Webinars
August 14, 2025 | 12:00 - 12:45 PM ET
Two additional sessions will be offered: August 18 – 12:00 – 12:45 (UTC +8:00) – Asia August 18 – 12:00 – 12:45 CET – Europe/Berlin
Medicare Part D is undergoing its most significant transformation in decades largely driven by the Inflation Reduction Act (IRA). What does this mean for pharmaceutical manufacturers?
Join us for an engaging discussion with Max Hunt, Partner at Trinity Life Sciences, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives…
Sign Up Now
Blog
Published July 1, 2025
China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the bar for clinical innovation, rewarding innovation that truly addresses unmet needs and demonstrates clear differentiation.
The National Reimbursement Drug List (NRDL) in China is a government-approved roster of medications that are covered by the national health insurance system. Inclusion on this list…
Read Now
Blog
Published June 25, 2025
Field sales serve as the primary bridge between companies and healthcare professionals to build trust, provide valuable information and drive product adoption. Effective call planning is essential, as it allows reps to prioritize their engagements, tailor messaging and maximize their impact.
The introduction of new technologies to streamline or enhance field operations comes with inherent challenges, such as resistance to change, training needs and aligning new systems with existing workflows. Quite simply, the field can become overwhelmed.
To overcome these…
Read Now
Blog
Published June 20, 2025
Reflecting on the first half of 2025 including data from AACR, ASCO and EHA, we see several notable trends continuing to shape the oncology landscape. While development follows momentum observed the last few years, these learnings provide a clearer understanding into the next wave of innovation.
Immunotherapy Moves Earlier in the Journey
One of the most notable themes is the continued momentum of PD-L1 therapies moving into earlier lines of treatment. New data supporting neoadjuvant use in solid tumors suggests…
Read Now
Blog
Published June 13, 2025
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to prepare for it.
What is the JCA?
The JCA is a centralized EU initiative designed to harmonize the clinical assessment component of Health Technology Assessments…
Read Now
Blog
Published June 9, 2025
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of ethics committee processes.
The MFG is a key part of Germany’s National Pharmaceutical Strategy, adopted by the federal cabinet in December 2023. This National…
Read Now
Webinars
Available On Demand
Join us for the first webinar in our “AI Innovations in Life Sciences” series to learn how generative AI (GenAI) can transform the way customer-facing teams (sales reps and medical science liaisons) operate in life sciences companies. Discover practical applications of GenAI to enhance call planning and customer engagement and help field teams translate data and analytics into action.Sales reps and MSLs face significant challenges in managing and synthesizing vast amounts of data from multiple sources. As companies prioritize the…
Watch Now
